About ImmuCell Corporation (NASDAQ:ICCC)
ImmuCell Corporation is an animal health company. The Company operates in the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries segment. The Company has developed products that provide immediate immunity to newborn dairy and beef cattle, and is developing product line extensions of its existing products that address mastitis. The Company's lead product, First Defense, is manufactured from cows' colostrum utilizing its vaccine and milk protein purification technologies. Its Wipe Out Dairy Wipes are made from a non-woven fabric that allows for a vigorous cleaning. It also developed California Mastitis Test (CMT), which is used for bulk tank, as well as individual cow sample monitoring and is used to determine which quarter of the udder is mastitic. Its product development initiative is Mast Out, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: NASDAQ:ICCC
- CUSIP: N/A
- Web: www.immucell.com
- Market Cap: $38.77 million
- Outstanding Shares: 5,048,000
- 50 Day Moving Avg: $6.67
- 200 Day Moving Avg: $6.40
- 52 Week Range: $4.76 - $7.98
Sales & Book Value:
- Trailing P/E Ratio: 88.28
- P/E Growth: 0.00
- Annual Revenue: $9.48 million
- Price / Sales: 4.09
- Book Value: $4.16 per share
- Price / Book: 1.85
- EBITDA: $1.65 million
- Net Margins: 4.55%
- Return on Equity: 2.25%
- Return on Assets: 1.75%
- Debt-to-Equity Ratio: 0.18%
- Current Ratio: 1.89%
- Quick Ratio: 1.28%
- Average Volume: 10,735 shs.
- Beta: 1.12
- Short Ratio: 5.24
Frequently Asked Questions for ImmuCell Corporation (NASDAQ:ICCC)
What is ImmuCell Corporation's stock symbol?
ImmuCell Corporation trades on the NASDAQ under the ticker symbol "ICCC."
How were ImmuCell Corporation's earnings last quarter?
ImmuCell Corporation (NASDAQ:ICCC) released its quarterly earnings results on Monday, August, 14th. The company reported ($0.05) earnings per share for the quarter. The company had revenue of $1.75 million for the quarter. ImmuCell Corporation had a return on equity of 2.25% and a net margin of 4.55%. View ImmuCell Corporation's Earnings History.
When will ImmuCell Corporation make its next earnings announcement?
Who are some of ImmuCell Corporation's key competitors?
Some companies that are related to ImmuCell Corporation include Tissue Regenix Group PLC (TRX), NovaBay Pharmaceuticals (NBY), NovaBay Pharmaceuticals (NBY), Vernalis plc (VER), Navidea Biopharmaceuticals (NAVB), CytRx Corporation (CYTR), Prima BioMed Ltd (PBMD), OvaScience (OVAS), ReNeuron Group Plc (RENE), Senomyx (SNMX), Sunesis Pharmaceuticals (SNSS), Bio-Path Holdings (BPTH), Genocea Biosciences (GNCA), Fibrocell Science (FCSC), Abzena PLC (ABZA), Scancell Holdings Plc (SCLP), Cleveland BioLabs (CBLI) and Aptose Biosciences (APTO).
Who are ImmuCell Corporation's key executives?
ImmuCell Corporation's management team includes the folowing people:
- David Scott Tomsche, Independent Chairman of the Board
- Michael F. Brigham, President, Chief Executive Officer, Treasurer, Secretary, Director
- Elizabeth Luttrell Williams, Vice President - Manufacturing Operations
- Paul R. Wainman, Director
- David S. Cunningham, Independent Director
- Jonathan E. Rothschild, Independent Director
Who owns ImmuCell Corporation stock?
ImmuCell Corporation's stock is owned by many different of retail and institutional investors. Top institutional shareholders include
ROTHSCHILD JONATHAN E
PESSIN NORMAN H
(9.51%). Company insiders that own ImmuCell Corporation stock include Brian L Pessin, David Cunningham, David Scott Tomsche and Joseph H Crabb. View Institutional Ownership Trends for ImmuCell Corporation.
How do I buy ImmuCell Corporation stock?
Shares of ImmuCell Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ImmuCell Corporation's stock price today?
MarketBeat Community Rating for ImmuCell Corporation (NASDAQ ICCC)MarketBeat's community ratings are surveys of what our community members think about ImmuCell Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of ImmuCell Corporation stock can currently be purchased for approximately $7.68.
Consensus Ratings for ImmuCell Corporation (NASDAQ:ICCC) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||No ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Consensus Price Target: ||N/A|Consensus Price Target History for ImmuCell Corporation (NASDAQ:ICCC)
Analysts' Ratings History for ImmuCell Corporation (NASDAQ:ICCC)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for ImmuCell Corporation (NASDAQ:ICCC)Earnings History by Quarter for ImmuCell Corporation (NASDAQ ICCC)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/9/2017|| || || || || || || || |
|8/14/2017||Q2 2017||($0.05)||$1.75 million||View||N/A|
|5/11/2017||Q1 2017||$0.12||$3.54 million||View||N/A|
|2/9/2017||Q416||$0.01||$2.70 million||$2.20 million||View||Listen|
|11/10/2016||Q316||$0.01||$1.61 million||$1.97 million||View||N/A|
|2/10/2016||Q315||$0.09||$2.21 million||$2.70 million||View||Listen|
|8/13/2015||Q215||$0.03||$1.54 million||$1.96 million||View||N/A|
|2/11/2015||Q414||$0.04||$1.56 million||$2.21 million||View||N/A|
|8/12/2014||Q214||($0.10)||$1.37 million||$1.54 million||View||N/A|
|2/13/2014||Q413||($0.05)||$1.42 million||$1.56 million||View||N/A|
|11/12/2013||Q313||$0.02||$1.08 million||$1.24 million||View||N/A|
|11/7/2012||Q312||($0.02)||$1.00 million||$1.08 million||View||N/A|
Earnings Estimates for ImmuCell Corporation (NASDAQ:ICCC)
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for ImmuCell Corporation (NASDAQ:ICCC)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for ImmuCell Corporation (NASDAQ:ICCC)
Insider Ownership Percentage: 20.10%Insider Trades by Quarter for ImmuCell Corporation (NASDAQ:ICCC)
Institutional Ownership Percentage: 15.56%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|7/27/2017||Brian L Pessin||Insider||Buy||30,000||$5.25||$157,500.00|| |
|3/14/2017||David Scott Tomsche||Director||Buy||2,000||$5.43||$10,860.00|| |
|11/7/2016||David Scott Tomsche||Director||Buy||4,000||$5.19||$20,760.00|| |
|7/8/2016||Joseph H Crabb||VP||Sell||1,935||$6.55||$12,674.25|| |
|7/7/2016||Joseph H Crabb||VP||Sell||2,691||$6.58||$17,706.78|| |
|7/5/2016||Joseph H Crabb||VP||Sell||5,374||$6.74||$36,220.76|| |
|3/21/2016||David Scott Tomsche||Director||Buy||955||$6.67||$6,369.85|| |
|1/29/2016||David Cunningham||Director||Buy||1,904||$5.25||$9,996.00|| |
|9/3/2015||Jonathan E. Rothschild||Director||Buy||3,000||$6.63||$19,890.00|| |
|9/1/2015||David Scott Tomsche||Director||Buy||1,000||$6.73||$6,730.00|| |
|8/31/2015||Jonathan E. Rothschild||Director||Buy||6,100||$7.37||$44,957.00|| |
|8/28/2015||David Scott Tomsche||Director||Buy||1,500||$7.27||$10,905.00|| |
|11/26/2014||Jonathan E Rothschild||Director||Buy||2,100||$4.82||$10,122.00|| |
|8/20/2014||Jonathan E Rothschild||Director||Buy||3,000||$4.55||$13,650.00|| |
|6/16/2014||Jonathan E Rothschild||Director||Buy||5,901||$4.57||$26,967.57|| |
|5/15/2014||David Cunningham||Director||Buy||1,500||$3.91||$5,865.00|| |
|8/23/2013||Jonathan E Rothschild||Director||Buy||1,500||$3.98||$5,970.00|| |
|8/16/2013||David Cunningham||Director||Buy||4,000||$3.68||$14,720.00|| |
Headline Trends for ImmuCell Corporation (NASDAQ:ICCC)
Latest Headlines for ImmuCell Corporation (NASDAQ:ICCC)
Loading headlines, please wait.
ImmuCell Corporation (ICCC) Chart for Tuesday, October, 24, 2017